38 related articles for article (PubMed ID: 24291446)
1. Recombinant production of Epstein-Barr virus BZLF1 trans-activator and characterization of its DNA-binding specificity.
Lim CS; Goh SL; Krishnan G; Ng CC
Protein Expr Purif; 2014 Mar; 95():8-12. PubMed ID: 24291446
[TBL] [Abstract][Full Text] [Related]
2. Construction and expression of a spliced variant of Epstein-Barr virus bzlf1 and preparation of its polyclonal antibody.
Qian L; Li D; Yang Z; Hu M; Yu M; Shi M; Shen B; Guo N
Prep Biochem Biotechnol; 2010; 40(1):46-56. PubMed ID: 20024794
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of lytic cycle activation by the Epstein-Barr virus ZEBRA protein.
Petosa C; Morand P; Baudin F; Moulin M; Artero JB; Müller CW
Mol Cell; 2006 Feb; 21(4):565-72. PubMed ID: 16483937
[TBL] [Abstract][Full Text] [Related]
4. The bZip dimerization domain of the Epstein-Barr virus BZLF1 (Z) protein mediates lymphoid-specific negative regulation.
Hong Y; Holley-Guthrie E; Kenney S
Virology; 1997 Mar; 229(1):36-48. PubMed ID: 9123876
[TBL] [Abstract][Full Text] [Related]
5. Overexpression, refolding, and purification of polyhistidine-tagged human retinoic acid related orphan receptor RORalpha4.
Lechtken A; Zündorf I; Dingermann T; Firla B; Steinhilber D
Protein Expr Purif; 2006 Sep; 49(1):114-20. PubMed ID: 16682227
[TBL] [Abstract][Full Text] [Related]
6. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
Adamson AL; Kenney SC
Virology; 1998 Nov; 251(1):187-97. PubMed ID: 9813214
[TBL] [Abstract][Full Text] [Related]
7. [Advances on zeta protein encoded by Epstein-Barr virus (EBV) BZLF1 gene].
Wang H; Cao Y
Ai Zheng; 2003 Oct; 22(10):1105-9. PubMed ID: 14558963
[TBL] [Abstract][Full Text] [Related]
8. Biophysical analysis of natural variants of the multimerization region of Epstein-Barr virus lytic-switch protein BZLF1.
Hicks MR; Balesaria S; Medina-Palazon C; Pandya MJ; Woolfson DN; Sinclair AJ
J Virol; 2001 Jun; 75(11):5381-4. PubMed ID: 11333921
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody.
Brousset P; Butet V; Chittal S; Selves J; Delsol G
Lab Invest; 1992 Oct; 67(4):457-64. PubMed ID: 1331609
[TBL] [Abstract][Full Text] [Related]
10. Low level of lytic replication in a recombinant Epstein-Barr virus carrying an origin of replication devoid of BZLF1-binding sites.
Feederle R; Delecluse HJ
J Virol; 2004 Nov; 78(21):12082-4. PubMed ID: 15479851
[TBL] [Abstract][Full Text] [Related]
11. Bioreactor-scale production and one-step purification of Epstein-Barr nuclear antigen 1 expressed in baculovirus-infected insect cells.
Meij P; Vervoort MB; de Gooijer K; Bloemena E; Meijer CJ; Middeldorp JM
Protein Expr Purif; 2000 Nov; 20(2):324-33. PubMed ID: 11049756
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
13. Design of peptide inhibitors that bind the bZIP domain of Epstein-Barr virus protein BZLF1.
Chen TS; Reinke AW; Keating AE
J Mol Biol; 2011 Apr; 408(2):304-20. PubMed ID: 21354428
[TBL] [Abstract][Full Text] [Related]
14. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1.
Schepers A; Pich D; Hammerschmidt W
Virology; 1996 Jun; 220(2):367-76. PubMed ID: 8661388
[TBL] [Abstract][Full Text] [Related]
15. Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells.
Imai K; Kamio N; Cueno ME; Saito Y; Inoue H; Saito I; Ochiai K
FEBS J; 2014 May; 281(9):2148-58. PubMed ID: 24588869
[TBL] [Abstract][Full Text] [Related]
16. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
[TBL] [Abstract][Full Text] [Related]
17. GST-tagged mouse estrogen receptor alpha-transactivation domain fusion protein is specifically degraded during its over-expression in E. coli and purification.
Thakur MK; Ghosh S
Mol Biol Rep; 2010 Mar; 37(3):1335-40. PubMed ID: 19319663
[TBL] [Abstract][Full Text] [Related]
18. Expression and purification of active WW domains of FBP11/HYPA and FBP28/CA150.
Kato Y; Sawano Y; Tanokura M
Protein Pept Lett; 2006; 13(2):197-201. PubMed ID: 16472085
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the cell-penetrating properties of the Epstein-Barr virus ZEBRA trans-activator.
Rothe R; Liguori L; Villegas-Mendez A; Marques B; Grunwald D; Drouet E; Lenormand JL
J Biol Chem; 2010 Jun; 285(26):20224-33. PubMed ID: 20385549
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human CIS2 (SOCS2) protein: subcloning, expression, purification, and characterization.
Biener E; Maurice S; Sandowski Y; Cohen Y; Gusakowsky EE; Hooghe R; Yoshimura A; Livnah O; Gertler A
Protein Expr Purif; 2002 Jul; 25(2):305-12. PubMed ID: 12135564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
